406 related articles for article (PubMed ID: 32950749)
21. Long-term clinical outcomes of patients with COVID-19 and chronic liver disease: US multicenter COLD study.
Aby ES; Moafa G; Latt N; Sultan MT; Cacioppo PA; Kumar S; Chung RT; Bloom PP; Gustafson J; Daidone M; Reinus Z; Debes JD; Sandhu S; Sohal A; Khalid S; Roytman M; Catana AM; Wegermann K; Carr RM; Saiman Y; Kassab I; Chen VL; Rabiee A; Rosenberg C; Nguyen V; Gainey C; Zhou K; Chavin K; Lizaola-Mayo BC; Chascsa DM; Varelas L; Moghe A; Dhanasekaran R
Hepatol Commun; 2023 Jan; 7(1):e8874. PubMed ID: 36633476
[TBL] [Abstract][Full Text] [Related]
22. Incidence of hepatocellular carcinoma among US patients with cirrhosis of viral or nonviral etiologies.
Mair RD; Valenzuela A; Ha NB; Ayoub WS; Daugherty T; Lutchman GA; Garcia G; Ahmed A; Nguyen MH
Clin Gastroenterol Hepatol; 2012 Dec; 10(12):1412-7. PubMed ID: 22902757
[TBL] [Abstract][Full Text] [Related]
23. Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study.
Simon TG; Hagström H; Sharma R; Söderling J; Roelstraete B; Larsson E; Ludvigsson JF
BMC Gastroenterol; 2021 Nov; 21(1):439. PubMed ID: 34814851
[TBL] [Abstract][Full Text] [Related]
24. Short-term outcomes of patients with chronic liver disease hospitalised with COVID-19.
Grgurevic I; Lucijanić M; Pastrovic F; Barisic Jaman M; Tjesic Drinkovic I; Zelenika M; Milosevic M; Medic B; Kardum D; Bokun T; Luksic I; Piskac Zivkovic N; Keres T; Grabovac V; Persec J; Barsic B
Intern Med J; 2022 Nov; 52(11):1891-1899. PubMed ID: 35555962
[TBL] [Abstract][Full Text] [Related]
25. Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma.
Sahasrabuddhe VV; Gunja MZ; Graubard BI; Trabert B; Schwartz LM; Park Y; Hollenbeck AR; Freedman ND; McGlynn KA
J Natl Cancer Inst; 2012 Dec; 104(23):1808-14. PubMed ID: 23197492
[TBL] [Abstract][Full Text] [Related]
26. Local geographic variation in chronic liver disease and hepatocellular carcinoma: contributions of socioeconomic deprivation, alcohol retail outlets, and lifestyle.
Major JM; Sargent JD; Graubard BI; Carlos HA; Hollenbeck AR; Altekruse SF; Freedman ND; McGlynn KA
Ann Epidemiol; 2014 Feb; 24(2):104-10. PubMed ID: 24332863
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcomes of patients with hepatitis B virus-related acute on chronic liver failure: An observational cohort study.
Lin S; Zhang K; Zhang J; Wang M; Velani B; Zhu Y
Liver Int; 2019 May; 39(5):854-860. PubMed ID: 30753752
[TBL] [Abstract][Full Text] [Related]
28. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
29. Principles of Care for Patients with Liver Disease During the Coronavirus Disease 2019 (COVID-19) Pandemic: Position Statement of the Saudi Association for the Study of Liver Disease and Transplantation.
Alqahtani SA; Aljumah AA; Hashim A; Alenazi TH; AlJawad M; Al Hamoudi WK; Alghamdi MY
Ann Saudi Med; 2020; 40(4):273-280. PubMed ID: 32564624
[TBL] [Abstract][Full Text] [Related]
30. Mortality Trends in Chronic Liver Disease and Cirrhosis in the United States, Before and During COVID-19 Pandemic.
Kim D; Bonham CA; Konyn P; Cholankeril G; Ahmed A
Clin Gastroenterol Hepatol; 2021 Dec; 19(12):2664-2666.e2. PubMed ID: 34256143
[TBL] [Abstract][Full Text] [Related]
31. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
Yang JD; Mohamed HA; Cvinar JL; Gores GJ; Roberts LR; Kim WR
Am J Gastroenterol; 2016 Nov; 111(11):1573-1580. PubMed ID: 27527741
[TBL] [Abstract][Full Text] [Related]
32. All coffee types decrease the risk of adverse clinical outcomes in chronic liver disease: a UK Biobank study.
Kennedy OJ; Fallowfield JA; Poole R; Hayes PC; Parkes J; Roderick PJ
BMC Public Health; 2021 Jun; 21(1):970. PubMed ID: 34154561
[TBL] [Abstract][Full Text] [Related]
33. Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: A multicentre United States experience.
Hashemi N; Viveiros K; Redd WD; Zhou JC; McCarty TR; Bazarbashi AN; Hathorn KE; Wong D; Njie C; Shen L; Chan WW
Liver Int; 2020 Oct; 40(10):2515-2521. PubMed ID: 32585065
[TBL] [Abstract][Full Text] [Related]
34. Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort.
Freedman ND; Cross AJ; McGlynn KA; Abnet CC; Park Y; Hollenbeck AR; Schatzkin A; Everhart JE; Sinha R
J Natl Cancer Inst; 2010 Sep; 102(17):1354-65. PubMed ID: 20729477
[TBL] [Abstract][Full Text] [Related]
35. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
36. Proton pump inhibitors are associated with accelerated development of cirrhosis, hepatic decompensation and hepatocellular carcinoma in noncirrhotic patients with chronic hepatitis C infection: results from ERCHIVES.
Li DK; Yan P; Abou-Samra AB; Chung RT; Butt AA
Aliment Pharmacol Ther; 2018 Jan; 47(2):246-258. PubMed ID: 29105111
[TBL] [Abstract][Full Text] [Related]
37. Effects of SARS-CoV-2 infection on incidence and treatment strategies of hepatocellular carcinoma in people with chronic liver disease.
Mak LY; Chung MSH; Li X; Lai FTT; Wan EYF; Chui CSL; Cheng FWT; Chan EWY; Cheung CL; Au ICH; Xiong X; Seto WK; Yuen MF; Wong CKH; Wong ICK
World J Hepatol; 2024 Feb; 16(2):211-228. PubMed ID: 38495273
[TBL] [Abstract][Full Text] [Related]
38. Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.
Canbay A; Kachru N; Haas JS; Sowa JP; Meise D; Ozbay AB
Aliment Pharmacol Ther; 2020 Oct; 52(7):1185-1194. PubMed ID: 33016540
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for hepatocellular carcinoma in patients with chronic liver disease: a case-control study.
Ha NB; Ha NB; Ahmed A; Ayoub W; Daugherty TJ; Chang ET; Lutchman GA; Garcia G; Cooper AD; Keeffe EB; Nguyen MH
Cancer Causes Control; 2012 Mar; 23(3):455-62. PubMed ID: 22258434
[TBL] [Abstract][Full Text] [Related]
40. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
